Edgewise Therapeutics, Inc.
EWTX
$11.42
-$0.15-1.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.88% | 26.97% | 22.79% | 24.96% | 33.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.89% | 43.46% | 49.01% | 49.52% | 59.59% |
| Operating Income | -38.89% | -43.46% | -49.01% | -49.52% | -59.59% |
| Income Before Tax | -33.60% | -38.98% | -42.67% | -39.61% | -48.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.60% | -38.98% | -42.67% | -39.61% | -48.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.60% | -38.98% | -42.67% | -39.61% | -48.08% |
| EBIT | -38.89% | -43.46% | -49.01% | -49.52% | -59.59% |
| EBITDA | -38.97% | -43.15% | -48.26% | -48.16% | -58.24% |
| EPS Basic | 7.98% | -5.65% | -14.05% | -15.47% | -24.21% |
| Normalized Basic EPS | 7.96% | -5.66% | -14.05% | -15.47% | -24.20% |
| EPS Diluted | 7.71% | -5.96% | -14.37% | -15.80% | -24.21% |
| Normalized Diluted EPS | 7.96% | -5.66% | -14.05% | -15.47% | -24.20% |
| Average Basic Shares Outstanding | 45.02% | 34.08% | 27.96% | 22.47% | 18.97% |
| Average Diluted Shares Outstanding | 45.02% | 34.08% | 27.96% | 22.47% | 18.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
